WO2023156911 - STABLE FORMULATIONS COMPRISING THIOTEPA
National phase entry:
Publication Number
WO/2023/156911
Publication Date
24.08.2023
International Application No.
PCT/IB2023/051366
International Filing Date
15.02.2023
Title **
[English]
STABLE FORMULATIONS COMPRISING THIOTEPA
[French]
FORMULATIONS STABLES COMPRENANT DU THIOTÉPA
Applicants **
SHORLA PHARMA LTD
Inventors
CUNNINGHAM, Sharon
RYAN, Orlaith
PLATTEEUW, Johannes Jan
Priority Data
63/310,638
16.02.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2950 | |
| EPO | Filing, Examination, Granting | 24540 | |
| Japan | Filing, Examination, Granting | 3170 | |
| South Korea | Filing, Examination, Granting | 4026 | |
| USA | Filing, Examination, Granting | 11340 |
Total:
46,026
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure provides pharmaceutical compositions comprising thiotepa, water, one selected from PEG, such as PEG400 or PEG600, and DMSO, and optionally thiosulfate or such compositions which is free or substantially free of impurities. Also provided is a method for treating cancer in a subject, or myeloablation prior to bone marrow transplantation using the composition. A method for enhancing the stability of a thiotepa formulation is also contemplated.[French]
La présente invention concerne des compositions pharmaceutiques comprenant du thiotépa, de l'eau, un élément choisi parmi le PEG, tel que PEG400 ou PEG600, et le DMSO, et éventuellement du thiosulfate ou de telles compositions qui sont exemptes ou sensiblement exemptes d'impuretés. L'invention concerne également une méthode de traitement du cancer chez un sujet, ou une myéloablation avant une greffe de moelle osseuse à l'aide de la composition. L'invention concerne en outre un procédé d'amélioration de la stabilité d'une formulation de thiotépa.